Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system.
Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days of supplies at not cost to the user.
“We are offering this program to help ensure people with diabetes have a choice when it comes to their treatment options,” chief commercial officer Bret Christensen said in prepared remarks.
“This zero cost trial is a simple way for Animas users to explore the only tubeless insulin delivery option in the United States. We realize this is a challenging time for Animas customers and Insulet is deeply committed to providing access to Omnipod and its unique benefits enjoyed by more than 100,000 customers across the globe.”
J&J is also evaluating another of its diabetes businesses, LifeScan, which makes the OneTouch line of blood glucose monitoring products, the company reported.